IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: M. MORIYA et al.	
Serial No. 10/556,932 Filed: November 16, 2005 For: 2-AMINOQUINOLINE DERIVATIVES	Art Unit: Examiner:
•	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERGK & CO., INC.

Date

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION			
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE		

If th	s is inconvenient, additional copies will be submitted upon request.
	. In accordance with 37 C.F.R. 1.97, (check one)
\checkmark	the attached information is filed within three months of the filing date of the captioned case.
	the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
	the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
	each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
	each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.
	no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.
	Poppostfully submitted

Respectfully submitted,
Catherine Date
By: CATHERINE D. FITCH
Attorney For Applicant(s)
Reg. No. <u>36,502</u>
MERCK & CO., INC.
Patent Dept., RY60-30
P.O. Box 2000
Rahway, N.J. 07065-0907
(732)594- <u>4 à 8-3</u>
Data: Feb 3 2001

S	ubstitute for form 1449A/PTO			COMPLETE IF KNOWN			
INFORMATION DISCLOSURE			CLOSURE	Application Number	10/556,932		
STATEMENT BY APPLICANT				Filing Date	November 16, 2005		
8	STATEMENT BY	AP	PLICANI	First Named Inventor	M. Moriya et al.		
			,	Group Art Unit			
	(use as many sheets as necessary)		Examiner Name				
Sheet	1	of	2	Attorney Docket Number	BY0025P		

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code known)		Date of Publication of Cited Document MM-DD-YYYY		
			-				

	FOREIGN PATENT DOCUMENTS						
Foreign Patent Document			Date of Publication of				
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	of Cited Document	Cited Document MM-DD-YYYY	
			WO 00/64877		Neurogen Corporation	11/02/2000	
			WO 02/02744		Synaptic Pharmaceutical Corporation	01/10/2002	
			WO 01/21577		Takeda Chemical Industries, Ltd.	03/29/2001	
			WO 99/48492		Japan Tobacco Inc.	09/03/1999	
			WO 03/045313		Merck & Co., Inc.	06/05/2003	
			EP 1 285 651		Takeda Chemical Industries, Ltd.	02/26/2003	
			WO 95/32967		SmithKline Beecham PLC	12/07/1995	
					· · · ·		

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

8	bstitute for form 1449B/PTO			COMPLETE IF KNOWN			
INFORMATION DISCLOSURE		Application Number	10/556,932				
COM A PROPERTY DAY A DRIVE I CANON				Filing Date	November 16, 2005		
5	STATEMENT BY APPLICANT			First Named Inventor	M. Moriya et al.		
			,	Group Art Unit			
	(use as many sheets as necessary)		Examiner Name				
Sheet	2	of	2	Attorney Docket Number	BY0025P		

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Kowalski et al., Exp. Opin. Investig. Drugs, Vol. 13 (2004), pp. 1113-1122, "Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity"
	AB	Clark et al., J. Med. Chem., Vol. 47 (2004), pp. 3962-3971, "A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor"
	AC	Arienzo et al., Bioorg. & Medicinal Chem. Letters, Vol. 14 (2004), pp. 4099-4102, Structure-activity relationshps of a novel series of melanin-concentrating hormone (MCH) receptor antagonists"
	AD	Kato et al., Chem. Abstracts, 134:266103, "Preparation of N-tetrahydronapththalenyl carboxamides as melanin concentrating hormone antagonists"
	AE	Antelman et al., Chem. Abstracts, 91:68543, "The importance of stress in assessing the effects of anorectic drugs"
	AF	Mueller et al., Chem. Abstracts 138:4532, "Preparation of quinolines as ligands for the neuropeptide Y receptor useful against arthritis, cardiovascular diseases, diabetes, renal failure, eating disordes and obesity"

	the state of the s		
Examiner		Date	
Signature		Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.